MicroRNA alterations have been reported in patients with Alzheimer 's disease (AD) and AD mouse models. We now report that miR-206 is upregulated in the hippocampal tissue, cerebrospinal fluid, and plasma of embryonic APP/PS1 transgenic mice. The increased miR-206 downregulates the expression of brain-derived neurotrophic factor (BDNF). BDNF is neuroprotective against cell death after various insults, but in embryonic and newborn APP/PS1 mice it is decreased. Thus, a specifi c microRNA alteration may contribute to AD pathology by downregulating BDNF.
INTRODUCTION
Alzheimer's disease (AD) is the most common cause of dementia in the population >65 years old [1] . It is associated with impairments in memory, language, behavior, and cognition [1] . The brain of AD patients is characterized by the presence of senile plaques and neurofibrillary tangles together with synaptic and neuronal cell loss [1] . Many microRNAs (miRNAs) have been implicated in AD [2] [3] [4] . miRNAs are a group of short (~21-23 nucleotides) non-coding RNAs [5] with conserved roles in Drosophila, rodents, monkeys, and humans [6] [7] [8] [9] . miRNA precursors are fi rst processed into singlestranded miRNAs that bind to the 3' untranslated region (UTR) of the complementary target mRNA sequences [10] , leading to translational repression or target degradation [11, 12] . A specifi c miRNA can have several hundred target gene sequences and regulate many pathways [13, 14] .
Neurotrophins have been reported to play important roles in the physiopathology of AD [15] . Brain-derived neurotrophic factor (BDNF) is the most widely expressed neurotrophin in the central nervous system [16] , and plays critical roles in neurite outgrowth, directional guidance, the induction of long-term potentiation, and neurotransmitter release [17] . It also regulates gene transcription, such as nuclear factor kappa B and c-Jun N-terminal kinase-p53-Bax, and activates intracellular signaling pathways, including Ras/mitogen-activated protein kinase, phosphatidylinositol 3/Akt, and phospholipase C pathways [18] . Moreover, BDNF has been associated with AD pathology. In cultured neurons, BDNF protects against amyloid β (Aβ) 1-42 toxicity [19] . It also rescues the damage induced by amyloid in rodent and primate models of AD [20] . On the other hand, Aβ 1-42 decreases BDNF expression in cortical neurons and affects its intracellular trafficking [21] . In AD transgenic mouse models, BDNF is negatively correlated with the cerebral amyloid burden [22] .
In addition, genetic association studies have linked BDNF polymorphisms to an increased risk of AD in humans [23] [24] [25] [26] .
Taken together, BDNF is implicated in AD pathogenesis.
In the present study, we set out to determine the mechanism of how BDNF is altered and whether some miRNA regulation is involved in such alteration. 
MATERIALS AND METHODS

Cell Culture
Primary neurons were cultured from embryonic day 14 (E14) APP/PS1 (APPswe/PS1E9) mouse hippocampus, following the regulations of Peking University Animal
Care and Use Committee as previously described [27] . SHSy5y cells were cultured with minimum essential medium (Invitrogen, Carlsbad, CA). and glutamate (Sigma) were stored in 100× stock solution and diluted with culture medium before use. Real-time PCR was done following the described procedure [28] . 
Reagents and
Western Blots and Measurement of Neuronal Cell Death
Western blots were performed following the protocols described previously [27] . Anti-BDNF (Abcam, Cambridge, UK) and actin (Sigma) antibodies were diluted at 1:1 000 for Western blots as primary antibodies. The relative density was calculated as the total absolute density of BDNF/actin control. Secreted BDNF was calculated by equal loading of the same volume of culture medium. Cell death was measured by terminal deoxynucleotidyl transferase-biotin dUTP nick-end labeling (TUNEL) using in situ cell death detection kit I according to the manufacturer's description (Roche, Quebec, Canada) [27] .
Luciferase Reporter Assays
The luminescence was expressed as relative light units [29] .
Enzyme-linked Immunosorbent Assay (ELISA)
ELISA kits were used to determine the concentrations of BDNF (R&D Systems, Minneapolis, MN) in the hippocampus, CSF, and plasma, as well as TrkA (R&D Systems), TrkB (R&D Systems) and p75 NTR (EIAAB Inc.) levels in the hippocampus of WT and APP/PS1 mice.
The relative optical intensity of each well was read by a microplate reader (BioRad 480; BioRad, Hercules, CA).
Statistical Analysis
Statistical signifi cance was assessed by one-way analysis of variance (ANOVA) followed by Sheffé's test. P <0.05 was taken as statistically signifi cant.
RESULTS
BDNF mRNA 3'UTR Was a Target of miR-206
In APP/PS1 mice at E14, the miR-206 level in the hippocampus was about 6-fold that in WT mice (Fig. 1A) .
As previous studies showed that miRNAs can be secreted into the CSF and plasma [2] , we also assessed their miR-206 levels, and found that both were upregulated in APP/ PS1 mice compared with the WT mice at E14 (Fig. 1A) .
The 3'UTR of human BDNF mRNA contains 3
complementary sequences for miR-206 (Fig. 1B) . In SH-Sy5y cells, luciferase reporter assays were performed (Fig. 1C, left panel) . In SH-Sy5y cells, the EGFP reporter assay confi rmed the inhibitory effect of miR-206 on the BDNF mRNA 3'UTR (Fig. 1C, right panel) .
To determine the specificity of miR-206 targeting BDNF mRNA, we tested other miRNAs with proposed roles in AD [3] against luciferase reporter activity regulated by the BDNF mRNA 3'UTR. Only miR-206 effectively inhibited luciferase activity (Fig. 1D) . We then mutated the BDNF mRNA 3'UTR complementary sequence and 2B ). With the BDNF mRNA 3'UTR, luciferase activity was greatly reduced in a BD dose-dependent manner (Fig. 2B) .
A time-course study showed that miR-206 began to inhibit luciferase activity from 12 h of treatment (Fig. 2C) . Western blotting further confirmed that miR-206 decreased the BDNF level (Fig. 2D) . miR-206 downregulated the levels of both BDNF in cellular extracts and secreted BDNF, whereas the miR-206 inhibitor increased both cellular and secreted BDNF (Fig. 2D ).
BDNF Was Decreased in AD Transgenic Mice and
Protected Against Cell Death ELISA showed that the BDNF level in hippocampal tissue was decreased in APP/PS1 mice compared with WT mice (Fig. 3A) at the E14 and newborn (P0) stages. The levels of BDNF in the CSF and plasma were also signifi cantly lower in APP/PS1 mice than in WT mice at both stages (Fig. 3A) .
We also assessed the levels of TrkA, TrkB, and p75 NTR , receptors for BDNF [18] , in hippocampal tissues at E14 and P0, and found no significant changes of TrkA and TrkB levels at either stage (Fig. 3B) . The p75 NTR level was lower in the APP/PS1 than in the WT mouse tissue (Fig. 3B) .
As neuronal loss has been demonstrated in AD pathology [1] , we then assessed the vulnerability of cultured WT and APP/PS1 neurons to various insults. Our data showed that extracellular Aβ 1-42 [27, [29] [30] [31] [32] , serum deprivation [31, 33] , staurosporine [31, 33] , Etop [31] and glutamate [34] induced more severe cell death in cultured APP/PS1 neurons than in WT neurons (Fig. 4) . Exogenous administration of BDNF at 1 μmol/L [35, 36] decreased the vulnerability of APP/PS1
neurons to all the above insults (Fig. 4) , suggesting that BDNF plays an important role in neuronal vulnerability and viability/death.
DISCUSSION
In the present study, we found that miR-206 was upregulated in transgenic APP/PS1 mice. A similar increase mice and in the temporal cortex of human AD brains [37] .
Furthermore, miR-206 targeted the 3'UTR of BDNF mRNA and decreased the BDNF level in AD transgenic mouse neurons, which is also consistent with the report that miR-206 targets BDNF transcripts [37] . Further, BDNF was protective against cell death induced by extracellular Aβ 1-42 , STS, Etop, serum deprivation, and glutamate.
The mechanism of BDNF protection is yet to be fully understood. It has been reported that Aβ 1-42 inhibits the BDNF-induced expression of Arc, an immediate-early gene responding to the BDNF signal, in cultured neurons [38] [39] [40] .
Arc is associated with synaptic plasticity and the induction of long-term potentiation [41] and may be linked to AD pathology. A reduced level of BDNF in AD has also been associated with increased pro-inflammatory activity [42] [43] [44] , alterations of oxidative stress and mitochondrial dysfunction [45] , downregulation of hippocampal neurogenesis [46, 47] , and GSK3β hyperactivity [48] [49] [50] . Further studies are needed to discover the mechanisms of miR-206 regulation in AD animal models and BDNF protection. Finally, AD has been considered to be an aging-related disorder. Our data showed that developmental defects, including microRNA regulation and BDNF expression and secretion may be involved in AD pathogenesis.
